Results 11 to 20 of about 31,151 (261)
Vaccines, 2021 SARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat ...
Acharya Balkrishna +10 more
doaj +1 more source
Virus-Like Particles as an Instrument of Vaccine Production [PDF]
Molecular Biology, 2019 The paper discusses the techniques which are currently implemented for vaccine production based on virus-like particles (VLPs). The factors which determine the characteristics of VLP monomers assembly are provided in detail. Analysis of the literature demonstrates that the development of the techniques of VLP production and immobilization of target ...
Syomin, B. V., Ilyin, Y. V.
openaire +3 more sources
Iranian Journal of Allergy, Asthma and Immunology, 2021 The widespread outbreak of coronavirus disease 2019 in late 2019 caused many people worldwide to die or suffer from certain clinical complications even after the recovery. The virus has many social and economic adverse effects.
Afshin Abdi Ghavidel +3 more
doaj +1 more source
Virus-like Particles as Preventive and Therapeutic Cancer Vaccines [PDF]
Vaccines, 2022 Virus-like particles (VLPs) are self-assembled viral protein complexes that mimic the native virus structure without being infectious. VLPs, similarly to wild type viruses, are able to efficiently target and activate dendritic cells (DCs) triggering the B and T cell immunities.
Anna Lucia Tornesello +4 more
openaire +3 more sources
COVID-19 vaccine and immune response
Exploration of Immunology, 2021 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; βCoV), the causative agent of coronavirus disease 2019 (COVID-19), causes severe lower respiratory tract infections and acute respiratory failure syndrome (ARDS).
Sevilay Hintistan, Hatice Demirağ
doaj +1 more source
Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines
Frontiers in Immunology, 2020 Prophylactic vaccines remain the best approach for controlling the human immunodeficiency virus-1 (HIV-1) transmission. Despite the limited efficacy of the RV144 trial in Thailand, there is still no vaccine candidate that has been proven successful ...
Chun-Wei Chen +5 more
doaj +1 more source
Epitope-Specific Anti-hCG Vaccines on a Virus Like Particle Platform.
PLoS ONE, 2015 The possibility of a contraceptive vaccine targeting human chorionic gonadotropin has long been recognized, but never fully realized. Here we describe an epitope-specific approach based on immunogenic display of hCG-derived peptides on virus-like ...
Jerri Caldeira +4 more
doaj +1 more source
Virus-like particles in vaccine development
Expert Review of Vaccines, 2010 Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. A handful of prophylactic VLP-based vaccines is currently commercialized worldwide: GlaxoSmithKline's Engerix (hepatitis B virus) and ...
António, Roldão +4 more
openaire +2 more sources
Virus-Like Particles As A Rotavirus Subunit Vaccine [PDF]
Journal of Infectious Diseases, 1996 Rotavirus subunit vaccines are being evaluated for use in humans. The virus-like particles (VLPs) for these vaccines are produced in insect cells coinfected with combinations of baculovirus recombinants expressing bovine RIF VP2 and simian SA11, VP4, VP6, or VP7 rotavirus proteins.
M E, Conner +12 more
openaire +2 more sources
Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges
Vaccines, 2023 The global outgoing outbreaks of Ebola virus disease (EVD) in different regions of Sudan, Uganda, and Western Africa have brought into focus the inadequacies and restrictions of pre-designed vaccines for use in the battle against EVD, which has affirmed ...
Sumira Malik +11 more
doaj +1 more source